Pro Medicus Ltd
ASX:PME
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/E
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Valuation Scenarios
If P/E returns to its 3-Year Average (163.7), the stock would be worth AU$367.77 (175% upside from current price).
| Scenario | P/E Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 59.6 | AU$133.84 |
0%
|
| 3-Year Average | 163.7 | AU$367.77 |
+175%
|
| 5-Year Average | 163.7 | AU$367.77 |
+175%
|
| Industry Average | 45.2 | AU$101.44 |
-24%
|
| Country Average | 22.3 | AU$50.03 |
-63%
|
Forward P/E
Today’s price vs future net income
| Today's Market Cap | Net Income | Forward P/E | ||
|---|---|---|---|---|
|
AU$12.1B
|
/ |
Jan 2026
AU$234.7m
|
= |
|
|
AU$12.1B
|
/ |
Jun 2026
AU$178m
|
= |
|
|
AU$12.1B
|
/ |
Jun 2027
AU$199.5m
|
= |
|
|
AU$12.1B
|
/ |
Jun 2028
AU$248.5m
|
= |
|
|
AU$12.1B
|
/ |
Jun 2029
AU$275.1m
|
= |
|
|
AU$12.1B
|
/ |
Jun 2030
AU$241.6m
|
= |
|
|
AU$12.1B
|
/ |
Jun 2031
AU$260.3m
|
= |
|
|
AU$12.1B
|
/ |
Jun 2032
AU$280.1m
|
= |
|
|
AU$12.1B
|
/ |
Jun 2033
AU$299.9m
|
= |
|
Forward P/E shows whether today’s P/E still looks high or low once future net income are taken into account.
Peer Comparison
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| AU |
|
Pro Medicus Ltd
ASX:PME
|
14.1B AUD | 59.6 | |
| JP |
|
Medical Data Vision Co Ltd
TSE:3902
|
37.9T JPY | 227.5 | |
| US |
C
|
Cerner Corp
LSE:0R00
|
31.3B USD | 53.1 | |
| US |
|
Veeva Systems Inc
NYSE:VEEV
|
25.9B USD | 28.5 | |
| JP |
|
M3 Inc
TSE:2413
|
1T JPY | 20.8 | |
| SE |
|
Sectra AB
STO:SECT B
|
49.7B SEK | 91.8 | |
| US |
W
|
Waystar Holding Corp
NASDAQ:WAY
|
4.8B USD | 42.2 | |
| US |
|
Doximity Inc
NYSE:DOCS
|
4.5B USD | 18.7 | |
| IN |
I
|
Inventurus Knowledge Solutions Ltd
NSE:IKS
|
267.3B INR | 40.3 | |
| US |
V
|
Vocera Communications Inc
F:V00
|
2.4B EUR | -328 | |
| CN |
|
Winning Health Technology Group Co Ltd
SZSE:300253
|
18.9B CNY | -61.4 |
Market Distribution
| Min | 0 |
| 30th Percentile | 15.9 |
| Median | 22.3 |
| 70th Percentile | 36.3 |
| Max | 5 709.2 |
Other Multiples
Pro Medicus Ltd
Glance View
Pro Medicus Ltd, an Australian company founded in 1983, has etched its name in the field of healthcare IT, primarily through its innovative medical imaging software solutions. The brainchild of Dr. Sam Hupert and Anthony Hall, the company originally sought to provide radiology practices with digital solutions for image management and viewing. Over the years, Pro Medicus has meticulously evolved its offerings to become a leader in picture archiving and communication systems (PACS), radiology information systems (RIS), and an expanding range of e-health solutions. Its flagship product, Visage 7, is renowned for delivering fast and sophisticated viewing capabilities, enabling radiologists to efficiently interpret complex imaging data. Under its hood, the company’s technology is powered by advanced streaming capabilities, allowing for large files to be quickly accessed and reviewed, essential for high-demand environments. The monetization model of Pro Medicus largely revolves around licensing agreements for its software, alongside service and support fees, ensuring a steady and recurring revenue stream. The company has successfully leveraged its expertise to penetrate key markets, notably the United States and Europe, where it partners with some of the most prestigious hospitals and research institutions. By focusing on high-end offerings and fostering long-term client relationships, Pro Medicus has cemented a premium positioning in the healthcare IT landscape. The strategic focus on innovation, coupled with a keen understanding of the evolving needs of healthcare providers, allows Pro Medicus to continually refine its services, ensuring it remains at the forefront of technological advancements that ultimately enhance diagnostic efficiency and patient outcomes.